Delivery Order SPE2DB20D3103-SPE2DB24FL8Z3
- Not listed
- The federal contract award is for the delivery of Mounjaro 7.5 mg/0.5 ml pen medication, valued at $1,993.76, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The contract does not have a set-aside...
- This federal contract award is for the delivery of the pharmaceutical product Mounjaro 7.5 mg/0.5 ml pen, 0.5 ml. The contract, valued at $9,038.75, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a delivery order with a firm fixed price, and the ultimate completion date is July 14, 2025. It is not designated as a set-aside contract, indicating open...
- This federal contract award is for the delivery of the pharmaceutical product Mounjaro 7.5 mg/0.5 ml pen 0.5 ml to the Defense Logistics Agency (DLA), a defense agency. The contract has a ceiling value of $2,453.66 and an ultimate completion date of May 7, 2024. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor. This appears to be a delivery order under a broader Indefinite Delivery Contract (IDC)...
- This federal contract award is for the delivery of the pharmaceutical product Mounjaro (15 mg/0.5 ml pen) to the Defense Logistics Agency (DLA). The contract has a ceiling value of $15,365.78 and a completion date of May 7, 2024. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a delivery order, with a firm fixed price pricing type. There is no set-aside designation for this award. Amerisourcebergen Drug Corp is a major...
- This federal contract award is for the delivery of the drug Mounjaro (7.5 mg/0.5 ml pen, 0.5 ml) to the Medical Supply Chain division of the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $4,574.47, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a delivery order with a firm fixed price and has an ultimate completion date of May 18, 2023. This contract does not have a set-aside designation, indicating it...
- This federal contract award is for the pharmaceutical product Mounjaro 7.5 mg/0.5 ml pen, 0.5 ml, with a ceiling value of $3,748.35 and a performance period ending on July 1, 2024. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. This is a delivery order contract with a firm-fixed-price pricing type. The contract does not have a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,052 firm-fixed-price delivery order is for the medication Mounjaro 7.5 mg/0.5 ml pen, with a completion date of November 14, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is for the pharmaceutical product MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The $24,225.11 firm fixed-price delivery order has an ultimate completion date of December 10, 2024. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has established itself as a key vendor for...
- This federal contract award is for the delivery of the pharmaceutical product Mounjaro 5 mg/0.5 ml pen, with a contract value of $8,161.08. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of May 2, 2023 and was awarded on May 1, 2023. This delivery order is placed under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA,...
- This federal contract award is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $7,302.24 and runs through December 27, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB24FL8Z3Delivery Order
This federal contract award is for the delivery of the pharmaceutical product Mounjaro 7.5 mg/0.5 ml pen (0.5 ml) to the Defense Logistics Agency (DLA). The award, valued at $1,052.00, was made to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. This is a firm fixed-price delivery order contract with an ultimate completion date of December 14, 2023. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 12/13/23 |